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Obsessive-compulsive disorder (OCD) is characterized by
recurrent and persistent thoughts (obsessions), and repetitive
behaviors or mental acts (compulsions). In Korea, an epide-
miological study reported that the lifetime prevalence of OCD
in the population was greater than two percent. The exact
cause of OCD is still unknown. Evidence from familial, twin
and segregation studies supports the role of a genetic com-
ponent in the etiology of OCD. In addition, there is growing
evidence that OCD has a specific neurochemical and neuro-
anatomical basis. According to this evidence, researchers have
selected various candidate genes which have been implicated
in the neurophysiology of OCD, and differences of allelic
variants in OCD patients and controls have been analyzed. In
this review we will introduce the results of previous genetic
studies of OCD which have been performed in other popu-
lations, including twin studies, family studies, segregation
analyses, linkage analyses, and association studies. In addition
to these studies, we will present the results of our genetic
studies of OCD performed in Korea.
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Obsessive-compulsive disorder (OCD) is charac-
terized by recurrent and persistent thoughts
(obsessions), and repetitive behaviors or mental
acts (compulsions). Most patients with OCD have
a chronic course of the illness and show a wide
range of functional impairment in occupational
and social areas. One epidemiological study
reported that about 3% of the general population
in the U.S. has experienced OCD.1 This preva-
lence is 20 times higher than previously expected.
This result suggests that OCD is more common
than schizophrenia or panic disorder, which are
both well-known by the general population. In
Korea, an epidemiological study2 reported that the
lifetime prevalence of OCD in urban and rural
populations were 2.29% and 2.14%, respectively.
The causes of OCD are still unclear, but there is
growing evidence that OCD has some specific
neurobiological bases, and that one of these is a
genetic component. The familial tendency of OCD
has been observed since the 1930s using genetic
studies of OCD. These included twin, family,
segregation, and association studies, and revealed
that some specific genes have an effect on the
development of OCD.3 Therefore, we reviewed in
this paper studies concerning the genetics of OCD
using various ethnic groups, including Koreans.
TWIN STUDIES
Many researchers have used twin studies to
estimate the relative importance of genetic and
environmental factors in the development of
OCD. If the concordance rate of a certain disorder
between monozygotic (MZ) twins is 100%, we can
conclude that the disorder is most likely purely
genetic. If the MZ concordance rate is less than
100%, it means that the disorder is likely caused
by a mixture of genetic and environmental factors.
Also, if the concordance rate between MZ twins
is much higher than that of dizygotic twins (DZ),
it can be considered that a genetic component
contributes substantially to the pathophysiology
of the disorder.
3
Inouye et al.
4
reported an 80%
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concordance rate of obsessional neurosis among
ten pairs of Japanese MZ twins, as compared to
a 50% concordance rate among four pairs of DZ
twins. Carey and Gottesman5 found an 87% con-
cordance rate of obsessive symptoms and features
between MZ twins (47% in DZ twins) from the
Maudsley Twin Register. In addition, the response
to clomipramine6 or sertraline7 has appeared to be
more similar in MZ twins than for DZ twins. Most
recently, van Grootheest et al.8 reviewed past twin
researches. They concluded that only the studies
which used a dimensional approach and analyzed
the data with Structural Equation Modeling have
convincingly shown that obsessive-compulsive
(OC) symptoms are heritable in children, with
genetic influences in the range of 45% to 65%. In
adults, studies suggest a genetic influence on OC
symptoms, ranging from 27% to 47%. In sum-
mary, although most twin studies have important
limitations, such as inconsistent diagnostic criteria
and small sample sizes, all the results consistently
found higher concordance rates for MZ twins than
for DZ twins. However, the fact that the MZ
concordance rate is not 100% indicates that envi-
ronmental factors, such as birth complications and
other physiological vulnerabilities, may have an
impact on the development of OCD.9
FAMILY STUDIES
Because family is not only a unit for genetic
transmission, but also a transmission of environ-
mental and cultural backgrounds, familial aggre-
gation is not sufficient to prove that the disorder
is genetically transmitted. The family study
method compares the rates of illness in families
with those in the general population. There are
two types of methods in family study: the family
history method and the family study method.
Family history method
The family history method is used to determine
the prevalence of a disease in relatives by relying
on a single informant to report diagnostic infor-
mation on all first-degree relatives. Lewis et al.10
reported a rate of 32.7% for pronounced obsessive
traits in a sample of 306 first-degree relatives of
patients with OCD. Rasmussen and Tsuang11
presented a family history of a clinical sample of
44 patients who met the DSM-III criteria for OCD.
They reported that 4.5% of parents of the OCD
patients met the full criteria for OCD and another
11.4% of parents had significant OC traits. A
number of first-degree relatives of these patients
also had probable OCD or obsessive traits. Riddle
et al.12 reported that 71% of the clinically referred
children with OCD had a parent with either OCD
or OC symptoms.
Family study method
The family study method uses a strategy of
obtaining diagnostic data by directly interviewing
all available relatives. This method relies on a
personal assessment of all first-degree relatives to
obtain diagnostic information. In 1992, Bellodi et
al.13 reported that the morbidity risk for OCD in
patients' families accounted for 3.4%. When 21
patients with an age of onset under 14 years were
examined, the morbidity risk in first-degree rela-
tives reached 8.8%, compared with 3.4% among
the relatives of 71 later-onset probands.13 Using a
structured interview, Paul et al.14 directly inter-
viewed all available first-degree relatives of 100
probands with OCD. They found that the rates of
OCD and subthreshold OCD were significantly
greater among relatives of probands with OCD
(10.3% and 7.9%, respectively) than among the
comparison subjects (1.9% and 2.0%, respectively).
Nestadt et al.15 also reported that the lifetime pre-
valence of OCD was significantly higher in cases
with OCD relatives when compared with control
relatives (11.7% vs. 2.7%). Probands with tics or
OC personality disorder were not more likely to
have relatives with OCD than those without these
features. Recently, two direct interview family
studies of OCD were published. Fyer et al.16
reported that a significantly higher risk for OCD,
but not other anxiety disorders, was found in
relatives of OCD probands when compared to
relatives of controls. There was no relationship
between the proband age at onset of OCD and the
strength of familial aggregation. However, the
same group17 found that, when relative diagnoses
were derived without the benefit of proband
informant reports, no evidence of familial OCD
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transmission was found. When diagnoses were
made including information from the proband
about the relative, evidence of familial OCD was
found, but only when the diagnostic threshold
was lowered to include cases with probable OCD
or OCD symptoms. Evidence for familial trans-
mission of OCD was found only when diagnoses
were made using information from the affected
proband about their relatives. Therefore, they
concluded that their own inconsistent results
suggest that OCD may be heterogeneous with
regard to familial transmission.
SEGREGATION ANALYSES
Once familial aggregation of OCD is established
by twin studies and family studies, the next step
is to determine whether the patterns within
families are consistent with genetic models.
Although segregation analysis cannot prove the
existence of genes, if the analyses reveal that the
patterns within families closely follow a pattern
predicted from basic Mendelian principles, genetic
factors are likely an essential factor in the cause
of the disorder.3 Five complex segregation an-
alyses have implicated a major locus in a pro-
portion of families with OCD.18-22 Nicolini et al.23
collected data from 24 OCD probands and re-
ported that either an autosomal dominant or
recessive model could not be rejected. Cavallini et
al.20 applied a complex segregation analysis to a
sample of 107 Italian families with probands with
OCD using regressive logistic models to test for
possible models of genetic transmission. For the
107 OCD families, the best fit was a dominant
model of transmission (with a higher penetrance
for females), but this did not include an expanded
phenotype (OCD + Tourette's syndrome + chronic
motor tics). In addition, Alsobrook et al.22 perform-
ed complex segregation analyses with families
ascertained through an OCD-affected proband.
Their segregation analyses used four factor-an-
alytic symptom dimensions to subset the family
sample based upon the probands' symptom factor
scores to resolve the phenotypic heterogeneity
observed among individuals with OCD. Analyses
limited to families' probands with high symmetry
and ordering symptoms led to rejection of the
polygenic model, indicating the involvement of a
major locus. However, they also could not identify
a specific Mendelian model. Nestadt et al.18 per-
formed complex segregation analyses of the 153
families (80 case and 73 control) included in the
Johns Hopkins OCD Family Study. They found
strong evidence that OCD involved a major gene
and conformed to a Mendelian-dominant model,
with significant sex effects and residual familial
effects. Recently, Hanna et al.19 studied 52 families
(35 case and 17 control families) through pediatric
probands (10 - 17 years). Their results of complex
segregation analyses provided evidence for a
major susceptibility locus in OCD when age at
onset was incorporated into the model. These
results suggest that the mode of inheritance may
be influenced by the residual effects of an affected
parent, which provides further evidence for the
etiologic heterogeneity of OCD. The dominant
Mendelian model provided a somewhat better fit
than the other Mendelian models.
In summary, the previous five segregation
studies indicate that the familial transmission of
OCD is caused by genetic factors. Although some
studies suggested a possible dominant model, the
mode of transmission is generally difficult to
model. This might be due to the fact that OCD is
an etiologically and clinically heterogeneous con-
dition. Thus, several genes may influence the
behavioral component of OCD, and a mixed
model involving several genes of major effect on
a multigenic background seems to fit the mode of
transmission of OCD.
LINKAGE ANALYSES
Once it has been demonstrated that genetic
transmission accounts for at least some of the
familiarity of a disorder, the next logical step is
to locate the susceptibility genes. The purpose of
a linkage study is to demonstrate that a DNA-
marker with known chromosomal localization
congregates with a disease in families.3 Weissbeck
et al.24 studied a three-generation family trans-
mitting OCD and tic disorders and reported that
the highest LOD score found was 1.3 in the 4p13
chromosome region. To date, several genome-
wide linkage studies of OCD have been pub-
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lished. Hanna and his colleagues25 analyzed a
genome scan in 56 individuals from seven families
ascertained through pediatric OCD probands; 27
of the 56 subjects had a lifetime diagnosis of
definite OCD. Their genome scan consisted of 349
microsatellite markers with an average between-
marker distance of 11.3 cM. They found that the
maximum multipoint LOD score with a dominant
model was 2.24 on 9p24. This result was also
replicated by Willour et al.26 when they genotyped
50 pedigrees with OCD using microsatellite
markers spanning the 9p24 candidate region. They
also reported that a 9p24 signal was observed in
both parametric and nonparametric linkage an-
alyses. Recently, Shugart et al.27 conducted a
genome-scan analysis of 219 families collected as
part of the OCD Collaborative Genetics Study.
Using the broad OCD definition, they observed
the strongest evidence for linkage was on chromo-
some 3q27-28. Covariate-linkage analyses impli-
cated a possible role of gene on chromosome 1 in
increasing the risk for an earlier-onset form of
OCD.
ASSOCIATION STUDIES
Whereas linkage analysis focuses merely on the
position of a tested marker, an association study
tests whether a particular allele of a marker, a
specific genotype, or a haplotype is statistically
associated with affected individuals when com-
pared to unaffected controls. Two design strate-
gies are employed in association studies: popula-
tion case-control designs and family-based asso-
ciation designs. Currently, the major approach
used in identifying OCD susceptibility genes has
been to compare the distribution of genotypes or
alleles of genes implicated in the neurophysio-
logy of OCD using population- or family-based
association studies.28
Genes related to serotonin neurotransmission
Studies performed over the last decade have
implicated the involvement of the serotonin (5-
HT) system in the pathophysiology of OCD. The
number of [3H] paroxetine binding sites in blood
platelets has been found to be significantly lower
in OCD patients than in normal controls.29 It has
also been reported that m-chlorophenylpiperazine
(m-CPP), a serotonergic agent, exacerbates OC
symptoms.30,31 In addition, the efficacy of selective
serotonin reuptake inhibitors (SSRIs) in the treat-
ment of OCD has lead to the hypothesis of a
serotonergic dysfunction in OCD. Therefore, most
widely-investigated candidate genes of OCD are
genes related to serotonergic neurotransmission.
Serotonin transporter gene
Since the serotonin transporter (5-HTT) is the
primary target of action of SSRIs, the 5-HTT gene
located on chromosome 17q12 may be a good
candidate for OCD treatment. The serotonin trans-
porter gene has a functional biallelic polymor-
phism in the promoter region,32 consisting of an
insertion (long allele, L) or a deletion (short allele,
S) of 44 bp, which has been shown to have a
significant effect on blood serotonin concentra-
tion.33 McDougle et al.34 used a family-controlled
transmission disequilibrium test (TDT) with a set
of 34 European-American family trios of OCD and
found that the association and linkage disequilib-
rium between the 5-HTT linked the promoter
region (5-HTTLPR) gene L allele with OCD. They
also reported that a poor response to SSRIs might
be related with the L allele. Bengel et al.35 re-
cruited 75 Caucasian OCD patients and 397 ethni-
cally-matched individuals from a non-patient con-
trol group and found that the patients with OCD
were more likely than controls to carry two copies
of the L allele (46.7% vs. 32.3%). However, Kinner
et al.
36
did not find any significant association
between the distribution of the 5-HTTLPR geno-
types and OCD in 54 OCD patients of Afrikaner
descent and 82 ethnically-matched control indi-
viduals. Camarena et al.37 analyzed the 5-HTTLPR
polymorphic system in 115 Mexican OCD patients
and 136 controls. They could not find a significant
association between the L allele and OCD in both
case-control and family-based designs, including
haplotype-based haplotype relative risk (HHRR)
and TDT. Many other studies performed in various
populations including Jewish,
38
German,
39
French,
40
etc.41 also did not find a significant association
between 5-HTTLPR polymorphism and OCD.
In Korea, there has been only one study of the
association between 5-HTTLPR and OCD. We
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genotyped and phenotyped both 124 OCD
patients and 171 normal controls but could not
find any association between 5-HTTLPR polymor-
phism and the development of OCD. However, in
the OCD group, patients with the L/L + S/L geno-
type had higher scores for the religious/somatic
factor derived from 13 main contents of the Yale-
Brown obsessive-compulsive symptom (Y-BOCS)
checklist than those with the S/S genotype.42 The
frequencies for the 5-HTTLPR genotype in our
sample revealed a higher percentage (63 - 64%) of
the S/S genotype and a very lower percentage
(3%) of the L/L genotype, which were quite dif-
ferent from those determined from a Western pop-
ulation, where a higher percentage (32 - 47%) of
the L/L genotype and a relatively lower percent-
age (14 - 15%) of the S/S genotype were found.35
Recently, other single-nucleotide variants have
been detected within HTTLPR,43 and one of them
is an A G SNP which is located 1,629 bp up-
stream of the transcription start point. Because this
G is a sequence variation that always occurs in the
context of the L allele of HTTLPR in which it alters
AP2 transcription factor binding and suppresses
transcription, the A and G alleles are referred to
as LA and LG. Therefore, the two L alleles LA and
LG, together with the S allele, comprise a triallelic
locus of 5-HTTLPR,44 and unrecognized LG alleles
in S/L and L/L genotypes can create the appear-
ance of S allele dominance because certain LG-
containing genotypes tend not to be high ex-
pressing.44 Hu et al.44 reported that the gain-of-
function LALA genotype was approximately twice
as common in 169 whites with OCD than in 253
ethnically matched controls, which means it has a
moderate (1.8 fold) effect on the risk of OCD. They
also analyzed a TDT test using 175 trios consisting
of probands with OCD and their parents, and they
found that the LA allele was overtransmitted to the
patients with OCD by twofold.
Serotonin receptor genes
Among many serotonin receptor subtypes, the
5-HT2A receptor has been the most important in
the etiology and treatment of OCD. The activation
of postsynaptic 5-HT2A and 5-HT2C receptors
may be important in the improvement of OCD
symptoms after treatment with an SSRI.45 Studies
in OCD patients showed blunted prolactin and
cortisol responses to 5-HT2 receptor agonists.46
Enoch et al.47 recruited and genotyped 101 Cau-
casian OCD patients (48 females, 53 males) and
138 control subjects (77 females, 61 males) and
found that the -1438A allele frequency was higher
only in female OCD patients and not in male
patients. Walitza et al.48 performed an association
analysis of 5-HT2A polymorphism in 55 German
children and adolescents with OCD, and also in
223 controls, and confirmed the association
between the -1438A allele of the 5-HT2A gene and
juvenile OCD. Meira-Lima et al.49 examined the
allelic and genotypic frequencies of the T102C and
C516T variants of the 5-HT2A gene in 79 Brazilian
OCD patients and 202 control subjects. Although
they did not find any significant differences in the
frequencies of allele and genotype for the T102C
5-HT2A gene polymorphism, they found a sig-
nificant association between C516T 5-HT2A gene
polymorphism and OCD. Tot et al.50 analyzed 58
Turkish OCD patients and 83 controls. Although
they could not find significant differences in geno-
type distribution for either T102C or -1438 G/A
polymorphism of 5-HT2A between the two
groups, they found that the TT genotype for
T102C and AA genotype for -1438 G/A polymor-
phism of 5-HT2A were significantly higher in the
patients with severe OCD compared to those with
moderate to severe OCD. Other studies did not
find a significant association between -1438 A/G
polymorphism28,38,51 or T102 polymorphism28 and
OCD.
Some researchers have found that the activation
of the 5-HT2C receptor induces self-grooming in
rats.
52
This result supports the hypothesis that
selective stimulation of central 5-HT2C receptors
exacerbates symptoms in OCD. It has also been
reported that m-CPP, which stimulates 5-HT2C
receptor, exacerbates OC symptoms.30,31 Theses
studies provide support for the possible involve-
ment of 5-HT2C receptors in the etiology of OCD.
Cavallini et al.53 investigated the role of the
Cys23Ser mutation of the 5-HT2C receptor gene in
OCD by performing an association study com-
paring a sample of 109 Italian OCD patients with
a sample of 107 healthy control subjects. However,
they did not find any allelic or genotypic associa-
tion between OCD and the 5-HT2C receptor gene.
Frisch et al.38 also performed a similar study in
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Jewish OCD patients and did not find any signifi-
cant association between 5-HT2C receptor poly-
morphism and OCD.
The 5-HT1D receptor appears to be particuβ -
larly interesting in the pathophysiology of OCD.
The 5-HT1D receptor is a terminal autoreceptorβ
involved in the regulation of 5-HT synthesis and
release, and is expressed mostly in the limbic
region and in the striatum. Gross-Isseroff et al.54
reported that sumatriptan, a selective 5-HT1Dβ
agonist, caused significant OCD symptom ex-
acerbation. In addition, Stern et al.55 found that
the continuous administration of sumatriptan
could reduce depression and OC symptoms in
three refractory OCD patients. To date, only
eight studies of the association between the 5-
HT1D gene and OCD have been reported. Twoβ
family-based association studies by Mundo et al.
56,57 reported that the G861 allele of the 5-HT1Dβ
gene was preferentially transmitted to OCD
patients. However, other family-based studies by
Camarena et al.,58 Di Bella et al.,59 and Walitza et
al.39 did not replicate this result. The other two
case-control studies28,60 also did not find any asso-
ciation between 5-HT1D G861C polymorβ phism
and OCD. In Korea, we investigated the asso-
ciation 5-HT1D G861C and OCD but could notβ
find any significant associations (unpublished).
Tryptophan hydroxylase (TPH) gene
TPH is the rate-limiting enzyme in the synthesis
of 5-HT. Therefore, it has been considered that the
variant in TPH may influence serotonin turnover
and behaviors controlled by serotonin, such as
OCD.61 To date, only three studies of the associa-
tion between the TPH1 or 2 genes and OCD have
been published. Frisch et al.38 found no asso-
ciation between TPH1 and Jewish OCD patients.
Walitza et al.
39
also did not find transmission
disequilibrium for alleles of the SNP rs1800532
(TPH1 gene) in patients with early onset OCD
using a TDT test. The TPH2 gene has been re-
cently found and received attention because its
mRNA was detected exclusively in the brain.62
Mossner et al.63 investigated the association
between TPH2, the gene of the novel brain-
specific TPH2, in OCD and its role in childhood
and adolescent-onset OCD. In analysis of the
SNPs, rs4570625 and rs456946 of TPH2, they
found a significant preferential transmission of
haplotype G-C to OCD. They also found a trend
of preferential transmission of the C allele of SNP
rs4565946 to the early-onset of OCD.
Genes related to dopamine neurotransmission
As mentioned above, the most prevailing
hypothesis on the mechanism of OCD is the sero-
tonin hypothesis. However, about 40% of OCD
patients do not respond to SSRIs, and some
patients show no convincing functional abnorma-
lities related to serotonin.64 Furthermore, the sero-
tonin system varies and is interrelated with other
neurotransmitters or neuronal circuits.64 Therefore,
apart from the main hypothesis suggesting sero-
tonin abnormalities, some authors have proposed
that dopamine could participate in the pathophy-
siology of OCD.65 When high concentrations of
dopamine-related drugs, such as amphetamine
and bromocriptine, were administered in animal
studies, stereotypic behaviors similar to the obses-
sive behaviors in OCD patients were observed.65
Administration of dopamine receptor inhibiting
drugs in combination with an SSRI reduced obses-
sive symptoms in OCD patients who had previ-
ously shown resistance to treatment with an SSRI
alone.66 Similarly, there have been reports that OC
symptoms have emerged during treatment with
clozapine, a dopamine receptor D4 (DRD4) antago-
nist.67 This evidence obtained from neuroanatomi-
cal and pharmacological data suggests that the
dopaminergic neurotransmitter system may also
be implicated in mediating OCD.
Dopamine transporter gene (DAT1)
The DAT1 gene is located on chromosome
5p15.3 and has 40 bp variable numbers of tandem
repeats (VNTR, with 3 - 11 repeats) on the 3'-un-
translated region.68 There is some possibility that
these VNTR have an effect on the gene expression
and the level of DAT1 protein in the brain.69
However, there have only been a few studies
examining the association between DAT1 and
OCD. Frisch et al.38 reported that there was no
association between the DAT1 gene and OCD in
Jews, and Hemmings et al.28 also did not find any
difference in the distribution of DAT1 VNTR
between the OCD and control groups. In Korea,
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we investigated the differences of genotype distri-
butions of the DAT1 gene between 115 OCD
patients and 160 normal controls.70 Because a
previous study showed that the 10-repeats allele
is reported to increase DAT1 gene expression
compared with the 7-, 9-, and 11-repeats alleles,71
we classified the genotype of DAT1 into 10/10-
repeats and non-10/10-repeats groups. However,
we did not find any significant association between
the DAT1 gene and OCD. Also, there were no sig-
nificant differences in total Y-BOCS scores, global
assessment of functioning scores, and total Hamil-
ton depression rating scale scores between the
patients with 10/10-repeats and non-10/10-
repeats genotypes in OCD patients. Considering
our results, in consideration with the combined
results of the two previous studies, suggest that
DAT1 gene polymorphism is not likely to confer
susceptibility to OCD.
Dopamine receptor genes
Because of the phenomena of emerging OC
symptoms after treatment with clozapine, the
DRD4 gene has been the focus of genetic studies
of OCD. The DRD4 gene was characterized by the
insertion of 2 - 10 of 48 bp imperfect tandem
repeats in the encoding region of the third exon.72
Billet et al.73 genotyped more than 118 Canadian
OCD patients for DAT1 (40 bp VNTR), DRD2
(TaqIA), DRD3 (MscI), and DRD4 (48 bp VNTR).
They found significant differences in allele fre-
quencies between patients and controls only for
the DRD4 gene. However, Frisch et al.
38
reported
that there were no significant differences of geno-
type distributions of DRD4 between OCD and
control patients. Hemmings et al.28 also reported
negative results in an Afrikaner population.
Meanwhile, Millet et al.74 found different results
from both a French family-based and population-
based association studies. In their study, an ex-
tended transmission-disequilibrium test for pre-
ferential allele transmission in OCD showed an
absence of transmission of 2-repeats allele of DRD4
gene (48 bp VNTR). In a population-based
association study, they found a significantly lower
frequency of 2-repeats allele in OCD than in con-
trols. Recently, a study showed a significantly
lower frequency of the DRD4 VNTR 7-repeat allele
of early onset OCD than that of late-onset OCD in
South African Caucasians, but not in Afrikaners.75
In Korea, we classified the DRD4 genes (48 bp
VNTR) of 115 OCD patients to the short genotype
(genotype with at least one copy of the 2-repeats)
and long genotype (genotype without a 2-repeats).
We could determine that the short genotype
frequency of DRD4 was significantly higher in
OCD patients than in normal control groups.76
However, contrary to a previous study by Hem-
mings et al.,75 we found no difference in genotype
frequencies between the early-onset OCD (age of
onset < 17) group and the late-onset OCD (age of
onset 17) group.76 In conclusion, there are still
inconsistent results of the association between the
DRD4 gene and OCD, but some studies74 (in-
cluding ours76) suggest the possibility that the
2-repeats allele or a nearby genetic variation could
have a protective effect against OCD symptoms.
There have only been a few studies on the DRD2
gene in OCD. Nicollini et al.51 performed an
association analysis of the DRD2 and DRD3 gene
in 67 OCD patients and 54 controls. Although
they did not observe any significant associations
between these genes and OCD, they found a
higher frequency of A2/A2 of DRD2 in OCD
patients with tics (N = 12). As mentioned above,
Billet et al.73 also did not find a significant asso-
ciation between DRD2 and OCD. Most recently,
Denys et al.77 examined 150 OCD patients (56
males) and 150 controls (79 males). They could not
find any significant differences in genotype distri-
bution of DRD2 between the two groups.
However, when they stratified the sample by
gender, they found higher frequency of the DRD2
A2 allele in male OCD patients compared to male
controls. However, their sample size of male OCD
patients seemed too small to draw a definite con-
clusion, and further analysis of larger samples is
warranted to confirm their data.
To date, there have been only three studies con-
cerning the associations between the DRD3 gene
and OCD. All of these studies showed no asso-
ciation between the Ser9Gly variant of DRD3 gene
and OCD.51,73,78
Genes related to the metabolism of neurotr-
ansmitters
Catechol-O-methyltransferase (COMT) is an en-
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zyme involved in the inactivation of catechol-
amines, including adrenaline, noradrenaline, and
dopamine. A polymorphism in the human COMT
gene (G472A) results in a valine (Val) to methi-
onine (Met) amino acid substitution (Val158Met)
and also reduces the activity of the enzyme to
one quarter of that encoded by the Val allele.79
The alleles are codominant, and heterozygotic
patients (Val/Met genotype) have intermediate
levels of COMT activity in comparison to homo-
zygous individuals.80 There have been several
studies about the possible role of the COMT
gene in OCD. Karayiorgou and colleagues per-
formed population-based81 and family-based
association82 studies and reported that in both
studies the low activity allele (Met158) is signifi-
cantly associated with susceptibility to OCD in
males only. Contrary to these results, Schindler
et al.83 used a family-based population analysis
and demonstrated a tendency for an association
between homozygosity (Met/Met or Val/Val) at
the COMT locus and OCD. Alsobrook et al. col-
lected 56 OCD probands and their parents, and
reported a mildly significant association with the
low-activity COMT allele in female probands of
OCD, but not in male probands. Their findings
of gender dimorphism contradict previous results
by Karayiorgou and colleagues.81,82 Meanwhile,
some researchers have reported that the hetero-
zygous genotype (Val/Met) was significantly
more common than expected in the Afrikaner
OCD population.84 However, other researchers
could not find any significant associations between
the COMT gene and OCD.
49,85,86
In Korea, we
analyzed the genotype of COMT in 124 OCD
patients and 170 normal controls, but we did not
find any differences of genotype distribution
between the two groups (unpublished).
MAOA is another important enzyme that de-
grades biogenic amines (noradrenaline, serotonin,
and, to a lesser degree, dopamine). There are two
polymorphisms which are related to the level of
enzymatic activity.87 The first polymorphism,
which is located 1.2 kb upstream of the MAOA
coding sequences, consists of a 30 bp repeated
sequence present in 2-, 3-, 3.5-, 4-, or 5-repeats,
and it has been designated MAOA-uVNTR. This
polymorphism is functional, in that 3.5-, 4- and 5-
repeats are transcribed 2-3 times more efficiently
than those with 3- and 2-repeats.88 The second
polymorphism is a T to C substitution on exon 14
(EcoRV), and the T allele is related to lower
enzyme activity.87 Camarena et al.89 examined the
MAO-A/EcoRV polymorphism in a sample of 122
OCD patients and 124 healthy subjects and found
that the T allele was associated with OCD in
female patients by family-based and population-
based association studies. However, Hemmings et
al.28 did not find any association between EcoRV
of the MAOA gene and OCD. In Korea, we
recruited 121 OCD patients (81 males and 40
females) and 276 controls (138 males and 138
females). In Korea, we found that male OCD
patients had a higher frequency of 3-repeats of
MAOA-uVNTR than normal male controls (64.2%
in OCD vs. 47.8% in control, unpublished), but we
did not find this association in female OCD
patients. Although more larger-scale studies are
warranted, our results (including several previous
studies82,89) indicate the possibility of an associa-
tion between the MAOA gene and OCD and its
gender dismorphic effects.
Other genes
In addition to monoamines, there have been
other putative neurotransmitters or neurotrophic
factors playing a role in the development of OCD,
such as glutamate, GABA, and brain-derived
neurotrophic factor (BDNF).
Using the family based association test, Arnold
et al.
90
tested for an association of the glutamate
receptor, ionotrophic, N-methyl-d-aspartate 2B
(GRIN2B) with OCD in 130 families and found
that GRIN2B may be associated with a suscepti-
bility to OCD. Regarding glutamate receptor
ionotropic kainate 2 (GRIK2) and 3 (GRIK3),
Delorme et al.
91
performed a case-control study in
156 patients and 141 controls, and also a transmis-
sion disequilibrium test in 124 parent-offspring
trios. Although there were no associations of
GRIK3 S301A or GRIK2 rs2227281 (intron 14) and
rs2227283 (exon 15) with OCD in the case-control
or family-based analyses, the GRIK2 SNP l867
allele (rs2238076) in exon 16 was transmitted less
than expected in OCD.
Recently, there has been increasing evidence
that the major inhibitory neurotransmitter, GABA,
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may also be functionally involved in OCD. Zai et
al.92 investigated five polymorphisms in the
GABA type B receptor 1 (GABBR1) gene in 159
OCD probands and their families using the TDT,
and they found a trend with an over-transmission
of the -7265A allele at the A-7265G polymorphism
in OCD.
Hall et al.93 evaluated a possible role of the
BDNF gene in 164 triads with OCD and suggested
that the Met66 allele, which affects the sequence
of the proBDNF protein, is undertransmitted and
likely confers a protective effect against OCD.
FUTURE DIRECTIONS
The genetic research of OCD has been much
advanced during the past decade. However, like
in other psychiatric disorders, the genetic study of
OCD has several limitations that should be
overcome. First, OCD is not a homogenous condi-
tion, and there might be various underlying etio-
logical mechanisms of OCD. Therefore, the ability
to define genetically valid subgroups of OCD is
crucial for genetic studies of OCD. Miguel et al.94
suggested several strategies for identifying valid
OCD phenotypes as follows. 1) The categorical
approaches: early-onset OCD phenotype, tic-re-
lated OCD phenotype and sensory phenomena as
a component of the OCD phenotype, and 2) the
dimensional approaches: OCD symptom dimen-
sions and quantitative personality traits related to
OCD. Another approach to identify more homo-
genous OCD subtypes is to find endophenotypes,
including brain-based markers (i.e., neuroimaging
and neurophysiological findings). Second, the
genotypes' distribution of genes is not the same
according to ethnicity. As mentioned above,
genotype distributions of various genes in Asians
(including Koreans) are quite different from those
in the Western population. Therefore, it could not
be assumed that the results from Western popu-
lations would be replicated in Asian populations,
including Koreans. In addition, most genetic
studies of OCD did not have a sufficient sample
size to draw clear conclusions. Therefore, if more
large-scale studies using large sample sizes would
be performed in various populations, it would be
helpful to understanding the genetic contribution
to OCD.
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